Having sealed approval in Europe for Beovu in wet age-related macular degeneration (AMD), Novartis AG is ready to hit the ground running and start taking market share from Bayer AG's rival VEGF inhibitor Eylea to treat the leading cause of severe vision loss and legal blindness in people over the age of 65.
Interview: Novartis's Big Hopes For Beovu
Drug Gets EU Okay For Wet AMD
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
